Brevibacterium sanguinis

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Brevibacterium sanguinis is a Gram-positive, non-spore-forming, aerobic, non-motile, coryneform bacterium. It has been detected in at least 1 gut microbiome compilation study or metastudy. The DNA G+C content is 69.9%. Brevibacterium sanguinis is probably a rare gut coloniser. (Wauters2004)



  • This organism has been recovered from clinical sources (blood, aspirate). The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. Is a rare opportunistic pathogen. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Wauters2004);
    Character Response
  • Substrates hydrolysed or digested:
  • casein; gelatin; tyrosine; xanthine;
  • 🧂
  • Salt tolerance:
  • tolerates 10% salt;
  • 🌡
  • Temperature tolerance:
  • grows at 20℃; grows at 37℃;
  • ⥅
  • Substrates assimilated or utilised:
  • N-acetylglucosamine; arabinose; fucose; gluconate; glucose; glycerol; inositol; maltose; sucrose; trehalose; D-turanose; γ-aminobutyrate; phenylacetate; quinate;
  • Active enzymes:
  • alkaline phosphatase; acid phosphatase; catalase; esterase C4; esterase lipase C8; α-glucosidase; Leu arylamidase; phosphoamidase;
  • ±
  • Strain-dependent active enzymes:
  • pyrrolidine arylamidase;
    • SPECIAL FEATURES
    Character Response
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Wauters2004);
    Class Active Resistant
  • Penicillins:
  • penicillin;
  • Cephalosporins:
  • cefotaxime; cephalothin;
  • Macrolides:
  • erythromycin;
  • Quinolines:
  • ciprofloxacin;
  • Aminoglycosides:
  • gentamicin;
  • Vancomycins:
  • vancomycin;

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Micrococcales Family:  Brevibacteriaceae Genus:  Brevibacterium Gram stain:  + O2 Relation.:  aerobic Spore:  No spore Motility:  Sessile Morphology:  Coryneform
    Health:  Unknown
    Source:  clinical sources (blood, aspirate)
    DNA G+C(%):  69.9
    Lower T(℃):  20(+)
    Mid T(℃):  37(+)
    NaCl >6%:  10(+)
    		Aesculin:  neg Urea:  neg Gelatin:  + Casein:  + Tyrosine:  +
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg Fructose:  neg Galactose:  neg Glucose:  neg Mannose:  neg Ribose:  neg Maltose:  neg Sucrose:  neg Trehalose:  neg Glycerol:  neg Mannitol:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Arabinose:  + Fucose:  + Glucose:  + Maltose:  + Sucrose:  + D-Turanose:  + Trehalose:  + N_Acetyl_glucosamine:  + Gluconate:  + Glycerol:  + Inositol:  + Mannitol:  neg 4-Aminobutyrate:  + Phenylacetate:  + Quinate:  +
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Catalase:  + Urease:  neg Ac-β-glcamnd:  neg α-Glucosidase:  + LeuAA:  + PyrrolidAA:  d AlkalineP:  + AcidP:  + Esterase(C4):  + EstLip(C8):  + Phosphoamidase:  +
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    penicillin:  Res
    cefotaxime:  Sens
    cephalothin:  Sens
    gentamicin:  Sens
    erythromycin:  Sens
    ciprofloxacin:  Sens
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    vancomycin:  Sens

    References

    SPECIFIC REFERENCES FOR BREVIBACTERIUM SANGUINIS
  • Wauters2004 - Identification of a novel Brevibacterium species isolated from humans and description of Brevibacterium sanguinis sp. nov.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR BREVIBACTERIUM SANGUINIS
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • ...............................
    • Added: February 09, 2022